ReviewVirulence2025
Next-generation antimicrobials: A review of phage lysins as precision weapons against drug-resistant pathogens.
Review in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.Clinical microbiology reviews · 2026Review
- Beyond the Barrier: Overcoming Ocular Antimicrobial Resistance Through AI and Novel Therapeutics.International journal of molecular sciences · 2026Review
- EV-LYSG101: Extracellular Vesicles Loaded With Lysin LYSG101 for Potent Anti-Staphylococcal Activity.Journal of extracellular biology · 2026Article
- Role of Disulfide Bond in Modulating the Antibacterial Activity and Structure of Cathelicidin-DM Peptides.Probiotics and antimicrobial proteins · 2026Article
- Examining the Effects: Lack of Impact by Endolysin and Phage Treatment on Rotifer and Larvae Microbiota.Antibiotics (Basel, Switzerland) · 2026Article
- Translational barriers to phage endolysin deployment for antimicrobial resistance control in Africa.Frontiers in antibiotics · 2026Review
- A chimeric, half-life extended lysin with a unique mode of action.Frontiers in microbiology · 2026Article
- Phage endolysins as alternative antimicrobials: mechanisms, clinical progress, and emerging resistance frameworks.Frontiers in microbiology · 2026Review
- Bacteriophage lysins: a promising strategy for combating foodborne pathogens in food safety.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The escalating misuse of antibiotics has precipitated a dramatic rise in bacterial drug resistance, rendering conventional therapies increasingly ineffective. In this post-antibiotic era, phage lysins have emerged as a novel class of antimicrobial agents, attracting significant attention for their precise targeting of drug-resistant pathogens. Despite promising preclinical results - highlighting their rapid bactericidal efficacy and synergistic potential with other antimicrobials - the clinical translation of lysins remains limited by unresolved challenges related to efficacy, safety, pharmacokinetics, and dosing optimization. This review provides a comprehensive overview of lysin research advancements, discusses diverse application strategies, and critically evaluates therapeutic outcomes from animal models and early clinical trials. Additionally, it addresses the key obstacles impeding lysin development and proposes practical solutions and future research directions to unlock the full clinical potential of this innovative antimicrobial strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.